Group 1 - The core point of the article highlights that in December 2025, the worst-performing ordinary equity and mixed funds were both managed by Baoying Fund, specifically the Baoying Medical Health Hong Kong-Shenzhen Stock A and C, which reported returns of -13.20% and -13.26% respectively [1] - The Baoying Innovation Medical Mixed Initiation A and C funds also performed poorly, with returns of -14.14% and -14.19%, making them the worst in the mixed fund category [1] - All these funds are themed around the medical sector and are managed by the same fund manager, Yao Yi, who has a background in research and fund management [1] Group 2 - The latest quarterly report indicates that the top ten holdings of the Baoying Medical Health Hong Kong-Shenzhen Stock fund include major companies such as Innovent Biologics, Kelun Pharmaceutical, and others, while the Baoying Innovation Medical Mixed Initiation fund shares many of the same top holdings [1][2] - Notably, several of these top holdings experienced significant declines in December, with the largest holding, Innovent Biologics, dropping by 18.97%, and another major holding, 3SBio, declining by over 22% [2] - The performance metrics of the funds show that the Baoying Innovation Medical Mixed Initiation C has a cumulative net value of 0.8857 and a scale of 0.51 billion, while the A share has a cumulative net value of 0.8886 and a scale of 0.47 billion [3]

Core Viewpoint - Yipinhong Pharmaceutical Group Co., Ltd. has announced the progress of its share repurchase plan, indicating that as of December 31, 2025, it has repurchased 2.6932 million shares, accounting for 0.60% of its total share capital, with a total expenditure of 93.8909 million yuan, nearing the lower limit of the repurchase plan of 100 million yuan [1][3]. Group 1: Repurchase Plan Background - The board of directors approved a share repurchase plan on December 15, 2025, intending to use self-owned and/or raised funds to repurchase A-shares through centralized bidding to maintain company value and shareholder rights [2]. - The repurchase plan sets a total fund range of no less than 100 million yuan and no more than 200 million yuan, with a maximum repurchase price of 70 yuan per share, and the implementation period is within three months from the board's approval [2]. Group 2: Repurchase Progress Details - As of December 31, 2025, the company has repurchased 2.6932 million shares through a dedicated securities account via centralized bidding, with the highest transaction price at 37.72 yuan per share, the lowest at 32.15 yuan per share, and an average transaction price of 34.86 yuan per share, totaling 93.8909 million yuan spent (excluding fees) [3]. - The repurchase actions comply with the established plan and relevant legal regulations, adhering to trading time and other restrictions as per the regulations [3]. Group 3: Future Arrangements - The company plans to continue implementing the share repurchase plan based on market conditions within the designated period and will fulfill its information disclosure obligations as required by laws and regulations [4]. - The implementation of this repurchase plan reflects the company's recognition of its value and confidence in future development, aiming to maintain shareholder rights and stabilize market expectations [4].

Group 1 - Ugreen Technology expects a net profit of 653 million to 733 million yuan for 2025, representing a year-on-year growth of 41.26% to 58.56% [1] - SenTai Co. plans to invest no more than 140 million yuan to establish a production base in Vietnam [2] - Muyuan Foods reported a December 2025 sales revenue of 9.667 billion yuan from commodity pigs, a year-on-year decline of 36.06% [3] Group 2 - Pumen Technology has received a medical device registration certificate for a quality control product used in various cancer markers [4] - Heng Rui Medicine's subsidiary has received approval for clinical trials of two injection drugs targeting obesity [5] - Quartz Co. was fined 2.7 million yuan for commercial secret infringement by its subsidiary [6] Group 3 - Chifeng Gold expects a net profit of 3 billion to 3.2 billion yuan for 2025, an increase of approximately 70% to 81% year-on-year [7] - Fulong Technology has terminated the transfer of 82.0969 million shares [8] - Senba Sensor's actual controller has released the pledge of 16.48 million shares [9] Group 4 - Hanma Technology reported a cumulative truck sales increase of 58.45% for 2025 [12] - Guankang Clean won a bid for a special procurement project worth 157 million yuan [14] - Defu Technology signed a cooperation agreement for high-end copper foil supply with a leading CCL company [15] Group 5 - Tianchen Medical signed a strategic cooperation agreement with Inspur Digital Technology [16] - CanSino received approval for clinical trials of a 24-valent pneumococcal polysaccharide conjugate vaccine [17] - Yipin Hong's subsidiary received approval for a supplementary application for oseltamivir phosphate capsules [19] Group 6 - Taotao Vehicle expects a net profit of 800 million to 850 million yuan for 2025, a year-on-year increase of 85.50% to 97.10% [20] - Yutong Bus reported a cumulative sales increase of 5.54% for 2025 [21] - Kingoo Co. received a notification from VinFast to supply automotive wheel products [22] Group 7 - ST Renfu's subsidiary received approval for clinical trials of a new drug for late-stage solid tumors [23] - Nanxing Co. expects a net profit of 90 million to 120 million yuan for 2025, reversing a loss from the previous year [24] - Jinrui Mining's subsidiaries will undergo routine maintenance starting January 5, 2026 [25] Group 8 - Changjiang Power reported a 3.82% increase in total power generation for its six hydropower stations in 2025 [26] - David Medical's subsidiary received a medical device registration certificate for an electronic endoscope image processor [28] - Guiguan Power reported a 26.68% increase in cumulative power generation for 2025 [29] Group 9 - ShenNan Electric's subsidiary won a project worth 208 million USD for a power plant operation service [30] - ST Kaiyuan's major shareholder's shares will be auctioned [31] - Jiecheng Co.'s major shareholder's shares have been auctioned [32] Group 10 - Tongbao Energy's wind power project has begun generating electricity [33] - Xusheng Group received an order worth 7.8 billion yuan from a North American EV manufacturer [34] - Qianli Technology reported a 154.08% increase in December 2025 electric vehicle production [35] Group 11 - Chint Electric plans to issue H-shares and list on the Hong Kong Stock Exchange [36][37] - Whirlpool expects a net profit increase of approximately 150% for 2025 [38] - Yongjie New Materials signed a 2 billion yuan aluminum alloy procurement contract [39]

Core Viewpoint - The announcement by Yipinhong indicates the approval of a new specification for Oseltamivir Phosphate Capsules, which is expected to enhance the company's product line and positively impact sales [1] Group 1: Company Developments - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for a supplemental application regarding Oseltamivir Phosphate Capsules [1] - The approval includes the addition of a 30mg specification, along with changes to quality standards and production processes [1] - This approval signifies that the company is now qualified to sell this specification of the drug in the domestic market, thereby enriching its product pipeline and categories [1]

格隆汇1月5日丨一品红(300723.SZ)公布，截至2025年12月31日，公司通过回购专用证券账户以集中竞 价交易方式累计回购公司股份数量为269.32万股，占公司总股本的0.60%，最高成交价为37.72元/股，最 低成交价为32.15元/股，成交均价为34.86元/股，已使用资金总额为9,389.09万元（不含手续费）。公司 上述回购实施情况符合既定回购方案及相关法律法规的要求。 ...

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for its Oseltamivir Phosphate Capsules, indicating a significant development in its product portfolio and potential market opportunities in influenza treatment and prevention [1] Group 1: Product Approval - The company’s wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a "Drug Supplement Application Approval Notice" for Oseltamivir Phosphate Capsules [1] - The approved indications for the drug include treatment for adults and children aged 1 year and older for both Type A and Type B influenza, with effective treatment if administered within 48 hours of symptom onset [1] - The drug is also approved for the prevention of Type A and Type B influenza in adults and adolescents aged 13 years and older [1] Group 2: Product Specifications - The company currently offers the drug in two dosages: 75 mg and 45 mg [1]

（记者 王晓波） 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 每经AI快讯，一品红1月5日晚间发布公告称，截至2025年12月31日，公司通过回购专用证券账户以集 中竞价交易方式累计回购公司股份数量为269.32万股，占公司总股本的0.6%，最高成交价为37.72元/ 股，最低成交价为32.15元/股，成交均价为34.86元/股，已使用资金总额为9389.09万元。 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the addition of a new specification of Oseltamivir Phosphate Capsules, indicating a positive development in its product portfolio [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a Drug Supplement Application Approval Notice for Oseltamivir Phosphate Capsules [1] - The approval includes the addition of a 30mg specification for the product, which expands its market offerings [1] - The approval also encompasses related supplementary applications, including changes to registration standards and production processes [1]

证券代码：300723 证券简称：一品红 公告编号：2026-001 一品红药业集团股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）于 2025 年 12 月 15 日 召开第四届董事会第十四次会议审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有资金及/或自筹资金以集中竞价方式回购公司部分已发行的人 民币普通股（A 股）股票用于维护公司价值及股东权益。 本次用于回购的资金总额为不低于人民币 10,000 万元且不超过人民币 20,000 万元。回购价格不超过人民币 70.00 元/股（含）。回购股份的实施期限为 自公司董事会审议通过本次回购方案之日起三个月内。本次回购股份方案在董事 会决策权限之内，无需提交股东大会审议。具体情况详见公司分别于 2025 年 12 月 16 日、2025 年 12 月 17 日披露于巨潮资讯网（http://www.cninfo.com.cn）的 《关于回购公司股份方案的公告》（公告编号：2025-089）、《回购报告书》（公告 ...

一品红药业集团股份有限公司 关于全资子公司获得磷酸奥司他韦胶囊药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州一品红 制药有限公司（以下简称"一品红制药"）于近日收到国家药品监督管理局核准 签发的关于磷酸奥司他韦胶囊的《药品补充申请批准通知书》，现将有关事项公 告如下： 证券代码：300723 证券简称：一品红 公告编号：2026-002 一、药品补充申请批准通知书主要信息 药品通用名称：磷酸奥司他韦胶囊 英文名/拉丁名：Oseltamivir Phosphate Capsules 剂 型：胶囊剂 注册分类：化学药品 规 格：30mg（按 C16H28N2O4计） 原药品批准文号：国药准字 H20223458 包装规格：10 粒/板，1 板/盒 药品注册标准编号：YBH35372025 申请内容：本次申请增加 30mg（按 C16H28N2O4计）规格，关联变更质量标准 （放宽含量限度、修订溶出度检查项对照品溶液配制浓度、在有关物质项下系统 适用性溶液要求里列明各杂质出峰 ...